Meg Alexander, head of the reputation and risk management practice at Syneos Health, and Jeff Stewart, managing director at Syneos Health Consulting, teamed up with MM&M to discuss implications of COVID-19 and the upcoming US election on drug pricing:
“COVID-19 will accelerate the conversation and keep it very relevant for 2021,” she (Meg Alexander) explains. “How individual companies communicate about the price of their therapies could accelerate the pointed discussions and make drug pricing persist as part of the 2021 agenda.”
“Political pressure not to have these products on formularies seems insurmountable in the face of double or triple profits,” says Jeff Stewart, managing director at Syneos Health Consulting. “As much as there’s a pricing pressure on manufacturers, keeping a COVID-19 treatment or vaccine off of a formulary seems inconceivable for an insurance company.”
Read more in this MM&M article.
This content was repurposed from MM&M.
